^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Astrocytoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Pilocytic astrocytoma, PXA, ganglioglioma if BRAF V600E activation mutation... BRAF/MEK inhibitors...Dabrafenib/trametinib...Vemurafenib/cobimetinib.
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    TAFINLAR is indicated, in combination with trametinib, for...the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Cancer Control
    Title:

    Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas

    Published date:
    10/08/2021
    Excerpt:
    We describe four patients with BRAF V600 E mutated gliomas, including a 21-year-old woman with a ganglioglioma WHO grade I, a 19-year-old man with a pleomorphic xanthoastrocytoma WHO grade III, and 21-year-old and 33-year-old women with epithelioid GBM WHO grade IV, who achieved durable progression-free survival with combination BRAF/MEKi.
    DOI:
    https://doi.org/10.1177/10732748211040013
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    CNS Oncol
    Title:

    Dabrafenib and trametinib in BRAFV600E mutated glioma

    Excerpt:
    ...a 48-year-old female with progressive anaplastic pleomorphic xanthoastrocytoma (PXA)….Immunohistochemistry for BRAFV600E was strongly positive,...She commenced treatment with the BRAF inhibitor dabrafenib (150 mg twice daily) in combination with the MEK inhibitor trametinib (2 mg once daily)....4 months following commencement of dabrafenib and trametinib shows continued reduction in the size of both solid and cystic disease, with further resolution of the mass effect (partial response by RANO criteria...
    DOI:
    10.2217/cns-2017-0006
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Neurosurg
    Title:

    Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity

    Excerpt:
    The authors treated 4 BRAF V600E patients, each with a different type of primary brain tumor (pilocytic astrocytoma, papillary craniopharyngioma, ganglioglioma, and pleomorphic xanthoastrocytoma) with the combination of dabrafenib and trametinib….The patients with pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and papillary craniopharyngioma experienced near-complete radiographic and complete clinical responses after 8 weeks of therapy.
    DOI:
    10.3171/2019.8.JNS19643